Table 3.
Significantly enriched pathway terms for DEGs in DLBCL. Functional and signaling pathway enrichment analyses of the DEGs were conducted using the DAVID website.
| Term | KEGG Pathway | Count | P Value | Genes |
|---|---|---|---|---|
| hsa05202 | Transcriptional misregulation in cancer | 7 | 0.00014 | NFKBIZ, FUT8, LMO2, CCND2, BCL2A1, ETV6, CDK14 |
| hsa04672 | Intestinal immune network for IgA production | 4 | 0.001522437 | CCR10, TNFRSF13B, AICDA, HLA-DOB |
| hsa05340 | Primary immunodeficiency | 3 | 0.011947217 | TNFRSF13B, AICDA, BLNK |
| hsa04640 | Hematopoietic cell lineage | 3 | 0.06510351 | IL2RA, CD44, MME |
| hsa04064 | NF-kappa B signaling pathway | 3 | 0.067811577 | CFLAR, BCL2A1, BLNK |
| hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 2 | 0.071387272 | FUT8, CHST2 |